Ketamine's rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors

Abstract

Ketamine is shown to enhance excitatory synaptic drive in multiple brain areas, which is presumed to underlie its rapid antidepressant effects. Moreover, ketamine's therapeutic actions are likely mediated by enhancing neuronal Ca2+ signaling. However, ketamine is a noncompetitive NMDA receptor (NMDAR) antagonist that reduces excitatory synaptic transmission and postsynaptic Ca2+ signaling. Thus, it is a puzzling question how ketamine enhances glutamatergic and Ca2+ activity in neurons to induce rapid antidepressant effects while blocking NMDARs in the hippocampus. Here, we find that ketamine treatment in cultured mouse hippocampal neurons significantly reduces Ca2+ and calcineurin activity to elevate AMPA receptor (AMPAR) subunit GluA1 phosphorylation. This phosphorylation ultimately leads to the expression of Ca2+-Permeable, GluA2-lacking, and GluA1-containing AMPARs (CP-AMPARs). The ketamine-induced expression of CP-AMPARs enhances glutamatergic activity and glutamate receptor plasticity in cultured hippocampal neurons. Moreover, when a sub-anesthetic dose of ketamine is given to mice, it increases synaptic GluA1 levels, but not GluA2, and GluA1 phosphorylation in the hippocampus within one hour after treatment. These changes are likely mediated by ketamine-induced reduction of calcineurin activity in the hippocampus. Using the open field and tail suspension tests, we demonstrate that a low dose of ketamine rapidly reduces anxiety-like and depression-like behaviors in both male and female mice. However, when in vivo treatment of a CP-AMPAR antagonist abolishes the ketamine's effects on animals' behaviors. We thus discover that ketamine at the low dose promotes the expression of CP-AMPARs via reduction of calcineurin activity, which in turn enhances synaptic strength to induce rapid antidepressant actions.

Data availability

Source Data files have been provided for Figures (Fig. 1-6) that contain the numerical data used to generate the figures.

Article and author information

Author details

  1. Anastasiya Zaytseva

    Molecular, Cellular and Integrative Neurosciences Program, Colorado State University, Fort Collins, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Evelina Bouckova

    Molecular, Cellular and Integrative Neurosciences Program, Colorado State University, Fort Collins, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. McKennon J Wiles

    Molecular, Cellular and Integrative Neurosciences Program, Colorado State University, Fort Collins, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Madison H Wustrau

    Department of Biomedical Sciences, Colorado State University, Fort Collins, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Isabella G Schmidt

    Molecular, Cellular and Integrative Neurosciences Program, Colorado State University, Fort Collins, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Hadassah Mendez-Vazquez

    Department of Biomedical Sciences, Colorado State University, Fort Collins, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Latika Khatri

    Department of Cell Biology, New York University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Seonil Kim

    Molecular, Cellular and Integrative Neurosciences Program, Colorado State University, Fort Collins, United States
    For correspondence
    seonil.kim@colostate.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0451-2180

Funding

Colorado State University

  • Anastasiya Zaytseva
  • Evelina Bouckova
  • McKennon J Wiles
  • Madison H Wustrau
  • Isabella G Schmidt
  • Seonil Kim

Boettcher Foundation

  • Seonil Kim

NIH/NCATS Colorado CTSA Grant (UL1 TR002535)

  • Seonil Kim

NIA (R03AG072102)

  • Seonil Kim

BrightFocus Foundation

  • Seonil Kim

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#3408) of Colorado State University. The protocol was approved by the Committee on the Ethics of Animal Experiments of Colorado State University. All surgery was performed under urethane anesthesia, and every effort was made to minimize suffering.

Copyright

© 2023, Zaytseva et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anastasiya Zaytseva
  2. Evelina Bouckova
  3. McKennon J Wiles
  4. Madison H Wustrau
  5. Isabella G Schmidt
  6. Hadassah Mendez-Vazquez
  7. Latika Khatri
  8. Seonil Kim
(2023)
Ketamine's rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
eLife 12:e86022.
https://doi.org/10.7554/eLife.86022

Share this article

https://doi.org/10.7554/eLife.86022

Further reading

    1. Neuroscience
    Cristina Gil Avila, Elisabeth S May ... Markus Ploner
    Research Article

    Chronic pain is a prevalent and debilitating condition whose neural mechanisms are incompletely understood. An imbalance of cerebral excitation and inhibition (E/I), particularly in the medial prefrontal cortex (mPFC), is believed to represent a crucial mechanism in the development and maintenance of chronic pain. Thus, identifying a non-invasive, scalable marker of E/I could provide valuable insights into the neural mechanisms of chronic pain and aid in developing clinically useful biomarkers. Recently, the aperiodic component of the electroencephalography (EEG) power spectrum has been proposed to represent a non-invasive proxy for E/I. We, therefore, assessed the aperiodic component in the mPFC of resting-state EEG recordings in 149 people with chronic pain and 115 healthy participants. We found robust evidence against differences in the aperiodic component in the mPFC between people with chronic pain and healthy participants, and no correlation between the aperiodic component and pain intensity. These findings were consistent across different subtypes of chronic pain and were similarly found in a whole-brain analysis. Their robustness was supported by preregistration and multiverse analyses across many different methodological choices. Together, our results suggest that the EEG aperiodic component does not differentiate between people with chronic pain and healthy individuals. These findings and the rigorous methodological approach can guide future studies investigating non-invasive, scalable markers of cerebral dysfunction in people with chronic pain and beyond.

    1. Neuroscience
    Ankur Sinha, Padraig Gleeson ... Robin Angus Silver
    Tools and Resources

    Data-driven models of neurons and circuits are important for understanding how the properties of membrane conductances, synapses, dendrites, and the anatomical connectivity between neurons generate the complex dynamical behaviors of brain circuits in health and disease. However, the inherent complexity of these biological processes makes the construction and reuse of biologically detailed models challenging. A wide range of tools have been developed to aid their construction and simulation, but differences in design and internal representation act as technical barriers to those who wish to use data-driven models in their research workflows. NeuroML, a model description language for computational neuroscience, was developed to address this fragmentation in modeling tools. Since its inception, NeuroML has evolved into a mature community standard that encompasses a wide range of model types and approaches in computational neuroscience. It has enabled the development of a large ecosystem of interoperable open-source software tools for the creation, visualization, validation, and simulation of data-driven models. Here, we describe how the NeuroML ecosystem can be incorporated into research workflows to simplify the construction, testing, and analysis of standardized models of neural systems, and supports the FAIR (Findability, Accessibility, Interoperability, and Reusability) principles, thus promoting open, transparent and reproducible science.